Thesis as of Jun 24, 2026
Passage Bio, a clinical-stage biotech company, is merging into Remix Therapeutics after the FDA asked for a randomized trial of its lead gene therapy for a rare inherited dementia; the combined entity will focus on REM-422, an mRNA-based cancer drug for adenoid cystic carcinoma that is not yet approved.
Passage Bio, built around PBFT02, a gene therapy for a rare inherited dementia, is being subsumed into Remix Therapeutics via reverse merger after FDA said it would not support a single-arm registrational trial and asked for a randomized trial the company judged not feasible. What survives is REM-422, an mRNA degrader in a registrational Phase 2 for adenoid cystic carcinoma, an unproven asset in a new modality with no efficacy data yet disclosed. The thesis now resolves entirely on whether REM-422 generates convincing ACC response data in 2027, with no approved therapies in that setting but an unvalidated mechanism carrying the full weight of the combined company.
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the Thesis, argued
Pipeline
3 programs · 5 catalysts
Disease areas: Other cancers, Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes